ArticleCommunications biology2026
Graphene quantum dot-coated mesoporous silica loaded with glucosamine sulfate as a potent antigen delivery system for immunoactivation.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graphene quantum dots (GQDs) belong to the carbon quantum dot family, with low toxicity, high biocompatibility, and excellent colloidal stability. Mesoporous silica nanoparticles (MSNs) are recognized as effective drug delivery systems due to their high drug-loading capacity, while glucosamine sulfate (GS) exhibits immunemodulatory properties. In this study, to maximize the immune effect of GS, a graphene quantum dot-coated mesoporous silica loaded with glucosamine sulfate (MSN-G-Q) is synthesized, and its immunoactivation effects are evaluated in vitro and in vivo. In vitro, MSN-G-Q enhances macrophage uptake activity, stimulates nitric oxide (NO) production, and upregulates CD80
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.